PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Empagliflozin Modestly Improves Liver Enzymes in MASLD, Not Lipids

empagliflozinSGLT-2 inhibitorMASLDNAFLDNASHliver enzymeslipid profileBMImeta-analysishepatic steatosistype 2 diabetes Endocrinology / Diabetes / Obesity

Background Information

Empagliflozin reduces liver enzymes in MASLD patients, showing promise.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common, linked to obesity and dyslipidemia, and lacks effective treatment options. Empagliflozin significantly reduced liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) and modestly reduced body mass index (BMI) but had no significant impact on lipid profiles. Empagliflozin may offer a modest benefit for liver enzyme reduction in MASLD, but the study's findings are limited by small sample sizes and short follow-up, requiring cautious interpretation. Empagliflozin shows potential benefits for liver enzyme reduction in MASLD but requires further research.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Karimi M, Tahmasebi A, Ramezanipour S, Rad FN, Valizadeh F, Abedi P, Gholami M, Sobhan Ardekani N, Pirshahid ME

Citation: Karimi M, Tahmasebi A, Ramezanipour S, et al. Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism. 2026;9(4):e70294. doi:10.1002/edm2.70294

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.